Aceragen (ACGN) 10-Q2016 Q1 Quarterly report

Filed: 9 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accretion, Advisory, Allocable, allocated, avoiding, calculated, category, Checkmate, clarify, classification, cohort, complicating, concealing, Cosmetic, de, dealing, decision, deemed, Deferral, defraud, deliverable, delivered, diminished, disgorgement, dispute, earned, effort, embedded, essential, exploit, false, forward, found, fraudulent, gap, gathering, GSK, HIPAA, iii, implanted, imprisonment, improbable, incremental, indirectly, individual, individually, induce, infused, inhaled, Innovation, innovative, inspection, instilled, insufficient, joint, JSC, knowingly, length, lessee, maximum, methodology, month, move, MTD, mutually, nonrefundable, Obama, opportunity, optimize, outpatient, oversee, owed, paragraph, PMA, Portability, PPACA, preempted, premarket, principle, privacy, purity, qui, rebate, RECIST, recommend, recommendation, regimen, reliably, remuneration, renal, reportedly, representation, repurchase, restitution, retrospective, reward, royalty, safeguarding, scheme, Serial, settled, shelf, soliciting, Squibb, standalone, standard, steering, stemming, straight, stringent, substantive, tam, teaching, traditional, transition, transmission, treble, untitled, vendor, violation, whistleblower, willfully, withholding, Yervoy

Removed: acquired, Actilon, activated, adjuvant, advocacy, aimed, Aldara, announced, assay, Australia, BioMarin, blood, carcinoma, cardioprotective, central, cetuximab, close, Coley, competitor, complementary, compound, concurrence, conditionally, convert, convertible, customary, cytotoxic, Darmstadt, death, discontinuation, DMD, downregulating, Duchenne, dystrophin, earliest, electrolyte, eliminated, Elimination, end, endpoint, excluding, executed, Exemption, expression, Exton, feet, flow, freely, Germany, Graceway, Group, GSO, harbor, head, HEPLISAV, Holding, imiquimod, improved, incidence, increasing, indemnification, infection, inflammation, informed, inhibition, initiating, iNova, leading, letter, manner, Meda, migration, modulator, neck, neutropenia, notified, organization, Parent, partnership, Pennsylvania, Pfizer, platform, play, practicable, presence, promoted, promptly, Prosensa, PTC, Pty, pursued, pursuing, Radiological, range, redeem, registered, Registrable, regulating, renewal, replacement, ReveraGen, Rule, Sarepta, SCCHN, screening, Secretary, September, silence, silencing, space, square, stimulate, subset, suspended, terminating, TOLAMBA, volunteer, worldwide, Zyclara

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ACGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS

ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Idera Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Vincent J. Milano, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement has been provided to Idera Pharmaceuticals, Inc. and will be retained by Idera Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



Dated: May 9, 2016				/s/ VINCENT J. MILANO
				Vincent J. Milano
				Chief Executive Officer